Skip to main content

Table 4 Treatment aims/advantages of neoadjuvant therapy

From: Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study

  surgeons oncologists
Which treatment aims do you associate with neoadjuvant therapy for PDAC?
 increasing the size of the resection margin (in resectable or borderline resectable cancer) 27/99 (27.3%) 4/15 (26.7%)
 decreasing the risk of distant metastases after an apparently curative resection by a preoperative treatment 27/99 (27.3%) 6/15 (40%)
 increasing the R0 resection rate (e.g. in borderline resectable cancer) 77/99 (77.8%) 14/15 (93.3%)
 achieving resectability/disease stabilization in oligometastasized disease with the aim of surgical treatment 16/99 (16.2%) 2/15 (13.3%)
 achieving secondary resectability in locally unresectable disease 54/99 (54.5%) 9/15 (60%)
 Preoperative treatment of micrometastases 35/99 (35.4%) 10/15 (66.7%)
What are the theoretical advantages of neoadjuvant over adjuvant treatment?
 better treatment tolerability of neoadjuvant treatment 41/99 (41.4%) 12/15 (80%)
 higher dosage possible during neoadjuvant treatment 26/99 (26.3%) 7/15 (46.7%)
 lower surgical complication rate after neoadjuvant treatment 11/99 (11.1%) 3/15 (20%)
 better oncological patient selection by neoadjuvant treatment 83/99 (83.8%) 13/15 (86.7%)
 better vascular supply of the tumor for neoadjuvant treatment 24/99 (24.2%) 6/15 (40%)